TMDX Share Price Performance
US$146.31
61.17 (71.85%)
3.1% overvalued intrinsic discount
US$141.91
Fair Value
Price US$146.31
AnalystConsensusTarget US$141.91
AnalystLowTarget US$114.00
AnalystHighTarget US$170.00
Fair ValueUS$141.91
Share Pricen/a
TransMedics Group, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 133 Fair Values set on narratives written by author
TMDX Community Narratives
AN
Fair Value US$141.91 3.1% overvalued intrinsic discount
TMDX: Expanding Organ Donor Pool And Clinical Trials Will Shape Future Direction
2users have liked this narrative
0users have commented on this narrative
56users have followed this narrative
AN
Fair Value US$114 28.3% overvalued intrinsic discount
Cost Pressures And Supply Risks Will Weaken Transplant Market Viability
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$170 13.9% undervalued intrinsic discount
Transplant Logistics Will Meet Demand From An Aging World
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
TMDX: Expanding Organ Donor Pool And Clinical Trials Will Shape Future Direction
Key Takeaways Rising global demand for organ transplants and healthcare modernization support broader adoption and revenue growth for TransMedics' OCS platform. Expansion into new organs, next-gen products, and recurring service offerings increase market potential and support stronger margins.Read more
2users have liked this narrative
0users have commented on this narrative
56users have followed this narrative
AN
US$141.91
3.1% overvalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
18% p.a.
Profit Margin
18.03%
Future PE
37.05x
Price in 2028
US$174.68
Transplant Logistics Will Meet Demand From An Aging World
Key Takeaways Dominance in next-generation organ transplant solutions, logistics, and comprehensive platforms positions TransMedics for rapid global share gains and recurring high-margin revenue growth. Structural healthcare trends and expansion into new geographies create a long runway for multi-organ adoption and sustained long-term revenue momentum.Read more
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$170
13.9% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
22% p.a.
Profit Margin
19.65%
Future PE
39.3x
Price in 2028
US$208.05
Cost Pressures And Supply Risks Will Weaken Transplant Market Viability
Key Takeaways Greater emphasis on preventive care and new therapies threaten future demand and technological relevance for the company's solutions. High costs, tightening healthcare budgets, and global risks may put ongoing pressure on margins, growth, and profitability.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$114
28.3% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue
18% p.a.
Profit Margin
13.4%
Future PE
43.88x
Price in 2028
US$141.07
Trending Discussion
Recently Updated Narratives
AN
TMDX: Clinical Trial Progress And US Market Dynamics Will Shape 2025 Outlook
Fair Value: US$141.91 3.1% overvalued intrinsic discount
56 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Cost Pressures And Supply Risks Will Weaken Transplant Market Viability
Fair Value: US$114 28.3% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Transplant Logistics Will Meet Demand From An Aging World
Fair Value: US$170 13.9% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
TransMedics Group, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- 2.69
- 60.28%
- 16.20%
- 144.1%
About TMDX
- Founded
- 1998
- Employees
- 728
- CEO
- WebsiteView website
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
